Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0948 • ACR Convergence 2020
Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus
Ricardo Grieshaber-Bouyer¹, Joshua Keegan², Peter Nigrovic³, James Lederer⁴ and Deepak Rao², ¹Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴BWH Harvard Medical School, Boston, MA
Background/Purpose: Neutrophils are important effector cells in systemic immune-mediated diseases. Neutrophil phenotypes vary depending on their age, maturity, activation state, and local environment; however, differences…
Abstract Number: 1019 • ACR Convergence 2020
Outdoor Air Pollution and Systemic Lupus Erythematosus
George Stojan¹, Anton Kvit², Frank Curriero² and Michelle Petri³, ¹Johns Hopkins University, BALTIMORE, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Understanding the role of environmental exposures in the development of SLE and their association with SLE activity may help identify modifiable risk factors and…
Abstract Number: 1257 • ACR Convergence 2020
Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
Sofia Gernaat¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Stanford Medicine, Stanford, CA, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Increased insulin resistance is pivotal in the development of gestational diabetes mellitus (GDM). Women with SLE may be at higher risk of GDM due…
Abstract Number: 1274 • ACR Convergence 2020
COVID-19 in Patients with Systemic Lupus Erythematosus
Ruth Fernandez-Ruiz¹, Mala Masson¹, Mimi Kim², Benjamin Myers³, Rebecca Haberman⁴, Jose Scher⁴, Rochelle Castillo⁴, Allison Guttmann¹, Philip Carlucci¹, Kristina Deonaraine¹, Michael Golpanian⁵, Kimberly Robins¹, Miao Chang¹, H. Michael Belmont⁶, Jill Buyon⁷, Ashira Blazer⁶, Amit Saxena⁸ and Peter Izmirly⁹, ¹New York University School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, ³Cornell University, Ithica, NY, ⁴NYU School of Medicine, New York City, ⁵New York University, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Department of Medicine, NYU School of Medicine, New York, NY, ⁸NYU School of Medicine, New York, ⁹Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for coronavirus disease 2019 (COVID-19) with biologic, genetic, demographic, clinical and…
Abstract Number: 1290 • ACR Convergence 2020
A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous
Mitra Moazzami¹, Patricia Katz², Dennisse Bonilla³, Lisa Engel⁴, Jiandong Su⁵, Pooneh Akhavan⁶, Nicole Anderson⁵, Oshrat Tayer-Shifman⁷, Dorcas Beaton⁸ and Zahi Touma⁹, ¹George Washington University School of Medicine, Washington, DC, ²University of California, San Francisco, Novato, CA, ³University Health Network, Toronto, Canada, ⁴University of Manitoba, Toronto, ON, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶Univesity of Toronto, Toronto, ON, Canada, ⁷Meir Medical Center, Raanana, Israel, ⁸Institue for Work and Health, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada
Background/Purpose: Use of The Patient Reported Outcomes Measurement Information System computerized adaptive test (PROMIS-CAT) in adults with systemic lupus erythematous (SLE) is an emerging research…
Abstract Number: 1454 • ACR Convergence 2020
B Cell-specific TLR7 Regulates Lupus in TLR9 Deficient Mice
Haylee Baxendell¹, Minjung Kim², Jeremy Tilstra² and Mark Shlomchik², ¹University of Pittsburgh, Cranberry Twp, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that results in significant morbidity and mortality. In SLE, endosomal TLR7 and TLR9 are known to…
Abstract Number: 1553 • ACR Convergence 2020
Optical Tomography Can Accurately Diagnose Lupus Arthritis
Wei Tang¹, Alessandro Marone², Youngwan Kim², Tommy Chen¹, Cathy Guo¹, Leila Khalili¹, Andreas Hielscher² and Anca Askanase³, ¹Columbia University Medical Center, New York, NY, ²Columbia University, New York, NY, ³Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Incapacitating inflammatory arthritis occurs in up to 88% of patients with systemic lupus erythematosus (SLE). Arthritis is present in 70-80% of lupus patients in…
Abstract Number: 1675 • ACR Convergence 2020
Microstructural Damage Is Associated with Age at Disease-onset and Cognitive Impairment in Systemic Lupus Erythematosus
Paulo Julio¹, Renan Frittoli¹, Aline Lapa¹, Thais Caldeira¹, Leticia Rittner¹, Fernando Cendes¹, Roberto Marini¹, Paula Fernandes¹, Lilian Costallat¹ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil
Background/Purpose: To compare corpus callosum (CC) volume and diffusion tensor imaging in systemic lupus erythematosus according to age of disease-onset. Methods: We selected 75 patients with…
Abstract Number: 1785 • ACR Convergence 2020
Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases
Jazzia Emily Diaz-Angulo¹, Cassandra M. Skinner-Taylor¹, Lorena Perez-Barbosa¹, Eugenio Salvador Barriga-Maldonado¹, Marco Valdovinos², Rita Pineda-Sic¹, Jesus Alberto Cardenas-de la Garza¹, Gabriel Figueroa-Parra³, Janett Carmen Riega-Torres⁴ and Dionicio Ángel Galarza-Delgado⁵, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey, Nuevo Leon, Mexico, ²Hospital Universitario José Eleuterio González, Monterrey, Nuevo Leon, Mexico, ³Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey NL, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The importance of safe and effective contraception for women with rheumatic diseases has been increasing. Several studies have demonstrated that carefully planned pregnancies are…
Abstract Number: 1805 • ACR Convergence 2020
Longitudinal Analysis of IFN Status and Disease Characteristics in SLE
Melissa Northcott¹, Alberta Hoi², Rachel Koelmeyer³ and Eric Morand⁴, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Monash University, Clayton, Victoria, Australia, ⁴Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: The type 1 interferon (IFN) cytokine family is key to the pathogenesis of SLE, evidenced by the expression of IFN stimulated genes (ISGs) in…
Abstract Number: 1822 • ACR Convergence 2020
Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy
Shiliang Wang¹, Richard Furie², Mary Anne Dooley³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Gerald Appel¹⁰, David Jayne¹¹, Sarah Hu¹², Sheng Gao¹³ and Michael Maldonado¹², ¹Bristol-Myers Squibb Company (at the time of analysis), Princeton, NJ, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of North Carolina, Chapel Hill, NC, ⁴University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶Organizacion Medica de Investigacion, Buenos Aires, Argentina, ⁷University of Padua, Padua, Italy, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ¹²Bristol-Myers Squibb Company, Princeton, NJ, ¹³Bristol-Myers Squibb Company (at the time of analysis), Princeton, NY
Background/Purpose: The ALLURE study compared efficacy and safety of abatacept (ABA) vs placebo (PBO) on background MMF and CS for the treatment of active proliferative…
Abstract Number: 1839 • ACR Convergence 2020
Medication Adherence Barriers and Opportunities to Overcome Them Among Patients with SLE
Lena Eder¹, Megan Clowse², Amanda Eudy³, Jennifer Rogers⁴, Rebecca Sadun³, Lisa Criscione-Schreiber⁵, Jayanth Doss³, Mithu Maheswaranathan⁶, Amy Corneli⁷, Hayden Bosworth⁶ and Kai Sun⁶, ¹Duke University Hospital, Chapel Hill, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Durham, NC, ⁴Duke University Hospital, Durham, DE, ⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, Duke University Medical Center, Durham, NC, ⁶Duke University Hospital, Durham, ⁷Duke University, Durham
Background/Purpose: Medication non-adherence in SLE is as high as 80%, yet little is known about adherence barriers faced by patients or interventions that improve adherence…
Abstract Number: PP07 • ACR Convergence 2020
Improving Communication with My Physician Drastically Improved My Health
Whitney Carter¹, ¹Lupus and Allied Diseases Association, Inc., Pleasanton, CA
Background/Purpose: In 2011, at the age of 14, I was sent to the emergency room with a platelet count of 19. The hematologist diagnosed me…
Abstract Number: 0243 • ACR Convergence 2020
The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus
Pooja Kumari¹, Viswanathan Ramakrishnan², Jihad Obeid², Diane Kamen³ and Jim Oates⁴, ¹The university of Tennesse Health Science center, Memphis, TN, ²medical university of south carolina, south carolina, ³Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that leads to significant morbidity and mortality. Therefore, it is essential to…
Abstract Number: 0259 • ACR Convergence 2020
Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
Shilpa Arora¹, Ehizogie Edigin² and Augustine Manadan¹, ¹Rush University Medical Center, Chicago, IL, ²John H Jr. Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: Guillain-Barré Syndrome (GBS) is a rare autoimmune polyneuropathy well described following viral illness, vaccination, or surgery. Systemic Lupus Erythematosus (SLE) has been associated with several…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].